Ezetimibe Interactions

Brand names: Ezetimibe

Dietary Cholesterol Absorption Inhibitor

Route: Oral

Contraindications

4 CONTRAINDICATIONS Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see Adverse Reactions (6.2) ]. When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1) ]. • Hypersensitivity to ezetimibe or any excipient of ezetimibe tablets. ( 4 ) • When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are insufficient data on ezetimibe use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits orally administered ezetimibe during the period of organogenesis at doses that resulted in up to 10 and 150 times, respectively, the human exposure at the MRHD, based on AUC (see Data) . Ezetimibe should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When ezetimibe is administered with a statin, refer to the Prescribing Information for the statin. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats (gestation days 6-15) and rabbits (gestation days 7-19), there was no evidence of maternal toxicity or embryolethal effects at the doses tested (250, 500, 1,000 mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1,000 mg/kg/day (~10 times the human exposure at 10 mg daily based on AUC 0-24hr for total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1,000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC 0-24hr for total ezetimibe). The animal-to-human exposure multiple for total ezetimibe at the no-observed effect level was 6 times for rat and 134 times for rabbit. Fetal exposure to ezetimibe (conjugated and unconjugated) was confirmed in subsequent placental transfer studies conducted using a mate

7 interactions on record

Combination increases exposure of ezetimibe and cyclosporine. Cyclosporine concentrations should be monitored; effect may be greater in severe renal insufficiency.

Source: NLP:ezetimibe

Co-administration not recommended; both drugs may increase cholesterol excretion into bile, leading to cholelithiasis.

Source: NLP:ezetimibe

Co-administration of ezetimibe with fibrates other than fenofibrate is not recommended until adequately studied due to potential cholelithiasis risk.

Source: NLP:ezetimibe

Cholestyramine decreases mean exposure of total ezetimibe, resulting in reduced efficacy. Administer ezetimibe at least 2 hours before or 4 hours after cholestyramine.

Source: NLP:ezetimibe

OATP1B1 substrate; eltrombopag may increase exposure. Monitor closely and consider dose reduction if appropriate.

Source: NLP:eltrombopag

OATP1B1 substrate; monitor for excessive exposure and consider dose reduction if appropriate.

Source: NLP:eltrombopag olamine

If ezetimibe is added to warfarin (a coumarin anticoagulant), the International Normalized Ratio (INR) should be appropriately monitored.

Source: NLP:ezetimibe